Towards the Validation of a New Blood Biomarker for the Early Diagnosis of Parkinson's Disease

Recruiting Observational Study
Parkinson Disease
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
70 (estimated)
Sponsor
University Hospital, Grenoble · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The investigators have recently discovered a metabolic biomarker which predicts Parkinson's disease (PD) at the early stages in patients and in animal models. The aim of BIOPARK is to investigate how the biomarker evolves in advanced PD stage, when diagnosis confirmation is higher, an in de novo PD patients who come from a different geographical area than those of the publication (since it is know…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Patients with de novo Parkinson's disease, without dopaminergic treatment * Patients with advanced Parkinson's disease (\> 5years) with dopaminergic treatment * Patients with multiple system atrophy Exclusion Criteria: * Patients with deep brain stimulation * Other neurodege…
Contacts

Florence Fauvelle, PhD

(33)456520600

florence.fauvelle@univ-grenoble-alpes.fr

CONTACT

Andrea Kistner, PhD

Akistner@chu-grenoble.fr

CONTACT